Llorens, Franc http://orcid.org/0000-0002-9756-7497
Hermann, Peter
Villar-Piqué, Anna
Diaz-Lucena, Daniela http://orcid.org/0000-0002-0262-1498
Nägga, Katarina http://orcid.org/0000-0003-0194-8402
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Santana, Isabel
Schmitz, Matthias
Schmidt, Christian
Varges, Daniela
Goebel, Stefan
Dumurgier, Julien
Zetterberg, Henrik
Blennow, Kaj
Paquet, Claire
Baldeiras, Inês
Ferrer, Isidro http://orcid.org/0000-0001-9888-8754
Zerr, Inga
Funding for this research was provided by:
Alzheimer's Drug Discovery Foundation (201810-2017419, 201810-2017419)
Instituto Carlos III
Instituto Carlos III
Alzheimer's Drug Discovery Foundation
Robert Koch Institute, German Federal Ministry of Health
Article History
Received: 14 March 2019
Accepted: 3 January 2020
First Online: 30 January 2020
Competing interests
: K.B. has served as a consultant or on the advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, all un-related to the data presented in the present paper. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen, Roche, and Fujirebio. H.Z. has served on scientific advisory boards for Eli Lilly, Roche Diagnostics, CogRx, Samumed, and Wave, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. C.P. is member of the International Advisory Boards of Lilly, is consultant of Fujiribio, ALZOHIS, NEUROIMMUNE, and GILEAD and is involved as investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astra-Zeneca, Lundbeck, and Neuroimmune. J.D. is an investigator in several passive anti-amyloid immunotherapies and other clinical trials for Roche, Eisai, Lilly, Biogen, Astra-Zeneca, Lundbeck. The remaining authors report no biomedical financial interests or potential conflicts of interest.